A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in With Advanced Nonsmall Cell Lung Cancer who have Progressed on Prior Anti-PD(L)1 Therapy and Chemotherapy (NCT04655976)
COSTAR
This trial is No longer recruiting
Registration number NCT04655976
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Maggie Moore
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR